Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.3%. By the end of trading, Pfizer fell $0.42 (-1.4%) to $30.40 on heavy volume. Throughout the day, 40,612,095 shares of Pfizer exchanged hands as compared to its average daily volume of 24,345,900 shares. The stock ranged in price between $30.21-$30.66 after having opened the day at $30.56 as compared to the previous trading day's close of $30.82. Other companies within the Drugs industry that declined today were:




), down 17.9%,

CytRx Corporation



), down 13.0%,

Oramed Pharmaceuticals



), down 11.4% and

Bacterin International Holdings



), down 10.0%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $195.1 billion and is part of the health care sector. The company has a P/E ratio of 13.6, below the S&P 500 P/E ratio of 17.7. Shares are up 0.6% year to date as of the close of trading on Thursday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,

Enanta Pharmaceuticals



), up 13.4%,

Idera Pharmaceuticals



), up 12.6%,

Ventrus Biosciences



), up 8.2% and

Tekmira Pharmaceuticals Corporation



), up 7.4% , were all gainers within the drugs industry with

Novo Nordisk A/S



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.